U079 Immunostaining in Mohs Surgery: Impact, Interpretation, and Implementation
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Immunostaining in Mohs surgery offers important advantages for interpreting frozen section histology in many clinical scenarios, such as for the treatment of melanoma, squamous cell carcinoma, extramammary paget's disease, merkel cell carcinoma, and dermatofibrosarcoma protuberans. Recent advances in the laboratory processing, clarity, and specificity of immunostains have facilitated growing adoption of the technique. This session will review the tumor characteristics and immunostains that have gained the most traction; delineate the protocols and commercially available antibodies to assist with implementation and quality improvement; and present cases and challenging scenarios to educate the audience on slide interpretation. As a result of increasing familiarity with the stains, faster processing, and lowering costs of the antibodies, Mohs surgeons in any practice setting can be empowered to integrate immunostaining into their routine.
LEARNING OBJECTIVES
Demonstrate the role and impact of immunostaining in Mohs surgery
Discuss framework for interpretation of immunostaining in frozen sections
Outline the steps to implementing immunostaining in a Mohs surgery laboratory
SPEAKERS
David G. Brodland, MD, FAAD
James Contestable, MD, FAAD
Catherine Motosko, MD, FAAD
Harrison P Nguyen, MPH, MBA, MD, FAAD
Junqian Zhang, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
David G. Brodland, MD, FAAD
No financial relationships exist with ineligible companies.
James Contestable, MD, FAAD
No financial relationships exist with ineligible companies.
Catherine Motosko, MD, FAAD
No financial relationships exist with ineligible companies.
Harrison P Nguyen, MPH, MBA, MD, FAAD
Castle Biosciences – Advisory Board(Honoraria);
Junqian Zhang, MD, FAAD
No financial relationships exist with ineligible companies.